LiPlasome Pipeline

LiPlasome Pharma’s most developed program is LiPlaCis® in clinical phase 1 trial. Further to this one preclinical programme is under development with Oxaliplatin as the active anti cancer agent.

In addition, the following drugs have successfully been encapsulated in our liposomes: doxorubicin, bleomycin, metotrexat, carboplatin, Ara-C and 5-FU.

LiPlasome Pipeline
 
Pipeline